Synapse - Works

Results (13087)

CPI-818, an oral interleukin-2-inducible T-cell kinase inhibitor, is well-tolerated and active in patients with T-cell lymphoma

Meeting Abstract

Khodadoust, M. S.; Feldman, T. A.; Yoon, D. H.; Yannakou, C. K.; Radeski, D.; Kim, Y. H.; Mehta-Shah, N.; Khot, A.; Wilcox, R. A.; Kim, W. S.; more...
Blood (2020)

Fulltext@MSK | Save

Association of patient activity bioprofiles with Hrqol and clinical responses: A prospective novel trial using mobile wearables in newly diagnosed multiple myeloma patients

Meeting Abstract

Korde, N.; Tavitian, E.; Derkach, A.; Zarski, A.; Salcedo, M.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Lendvai, N.; Smith, E. L.; more...
Blood (2020)

Fulltext@MSK | Save

A TCR mimic antibody-directed CAR T cell specific for intracellular NDC80 is broadly cancer reactive and displays high activity against hematological malignancies

Meeting Abstract

Klatt, M. G.; Yang, Z.; Liu, J.; Korontsvit, T.; Mun, S. S.; Peraro, L.; Gardner, T. J.; Bourne, C.; Dacek, M. M.; Dao, T.; more...
Blood (2020)

Fulltext@MSK | Save

Efficacy and safety of ponatinib (PON) in patients with chronic-phase chronic myeloid leukemia (CP-CML) who failed one or more second-generation (2G) tyrosine kinase inhibitors (TKIs): Analyses based on PACE and OPTIC

Meeting Abstract

Kantarjian, H. M.; Deininger, M. W.; Abruzzese, E.; Apperley, J.; Cortes, J. E.; Chuah, C.; DeAngelo, D. J.; DiPersio, J. F.; Hochhaus, A.; Lipton, J. H.; more...
Blood (2020)

Fulltext@MSK | Save

Treatment of high risk (HR) smoldering multiple myeloma (SMM) with carfilzomib, lenalidomide, and dexamethasone (KRd) followed by lenalidomide maintenance (-R): A phase 2 clinical and correlative study

Meeting Abstract

Kazandjian, D.; Hill, E.; Morrison, C.; Dew, A.; Korde, N.; Mailankody, S.; Manasanch, E. E.; Kwok, M. L.; Bhutani, M.; Tageja, N.; more...
Blood (2020)

Fulltext@MSK | Save

Loss of (TET2) uncouples proliferative and effector functions in CAR T cells

Meeting Abstract

Jain, N.; Zhao, Z.; Iyer, A. S.; Lopez, M.; Feucht, J.; Koche, R. P.; Zhan, Y.; Sadelain, M.
Blood (2020)

Fulltext@MSK | Save

COVID-19 impact on lymphoma patients' clinical outcomes - An observational cohort study

Meeting Abstract

Ip, A.; Mato, A.; Intrator, J.; Howard, N. P.; Petrillo, A.; Vicioso, R.; Sebti, R.; Cicogna, C.; Magarelli, G.; Leslie, L. A.; more...
Blood (2020)

Fulltext@MSK | Save

Trial-in-progress: Frontline brentuximab vedotin and CHP (A+CHP) in patients with peripheral T-cell lymphoma with less than 10% CD30 expression

Meeting Abstract

Jagadeesh, D.; Sims, R. B.; Horwitz, S. M.
Blood (2020)

Fulltext@MSK | Save

Outcomes of patients (pts) in ZUMA-9, a multicenter, open-label study of axicabtagene ciloleucel (axi-cel) in relapsed/refractory large B cell lymphoma (R/R LBCL) for expanded access and commercial out-of-specification (OOS) product

Meeting Abstract

Jacobson, C. A.; Locke, F. L.; Miklos, D. B.; Vose, J. M.; Lin, Y.; Budde, L. E.; Maloney, D. G.; Jaglowski, S.; Riedell, P. A.; Lekakis, L. J.; more...
Blood (2020)

Fulltext@MSK | Save

Clinical impact of bridging therapy prior to commercial chimeric antigen receptor (CAR) T-cell therapies for relapsed/refractory lymphomas

Meeting Abstract

Imber, B. S.; Perales, M. A.; Flynn, J.; Ruiz, J. D.; Devlin, S.; Alarcon Tomas, A.; Hajj, C.; Batlevi, C. L.; Dahi, P. B.; Lin, R. J.; more...
Blood (2020)

Fulltext@MSK | Save